http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003212072-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-06 |
| filingDate | 2003-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60419c6f9b2e158c2df2b8c9d630c87e |
| publicationDate | 2003-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2003212072-A1 |
| titleOfInvention | Salts of zopolrestat |
| abstract | This invention relates to [4-oxo-(5-trifluoromethyl-benzothiazol-2-ylmethyl)-3,4-dihydro-phthalazin-1-yl]-acetic acid ethanolamine salt, pharmaceutical compositions thereof and methods of treating diabetic complications in mammals comprising administering to said mammals said salt and said compositions. This invention is also directed to combinations of said diethylamine salt with NHE-1 inhibitors, selective serotonin retuptake inhibitors (SSRIs), glycogen phosphorylase inhibitors (GPIs), sorbitol dehydrogenase inhibitors (SDIs) and antihypertensive agents. Said combinations are useful in treating diabetic complications in mammals. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8226977-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8414920-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014126885-A1 |
| priorityDate | 2000-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1992.